Example: biology

Tuesday, 15 May 2018 Registration and Welcome …

Tuesday, 15 May 2018 Break08:00 - 09:30 FoyerRegistration and Welcome CoffeePlenary Session09:30 - 10:00 Congress HallWelcome Address 09:30 - 10:00 CIMT President Christoph HuberPlenary Session10:00 - 11:30 Congress HallCellular TherapyChair: Harpreet Singh (Immatics Biotechnologies, Houston, United States) 10:00 - 10:30 New modes of T-cell cancer recognition by dissection of immunotherapysuccesses Speaker: Andrew Sewell (Cardiff University, Cardiff, United Kingdom) 10:30 - 11:00 ADAP ting to solid tumors, advances and challenges for TCR T-cell therapy Speaker: Gwen Binder-Scholl (Adaptimmune, Philadelphia, United States) 11:00 - 11:30 TIL therapy in melanoma: history of clinical development, current statusand plans for the future Speaker: Rodabe Amaria (University of Texas MD Anderson Cancer Center,Houston, United States)Break11:30 - 13:30 FoyerLunchCorporate Supported Symposium12:00 - 13:00 Congress Hall"Immunooncology 2018 and beyond" supported by Bristol-Myers SquibbChair: Dirk J ger (National Center for Tumor Diseases, Heidelberg, Germany)Page 1 / 24 CIMT 2018 Scientific Programme 12:00

HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of Tuesday, 15 May 2018 Registration and Welcome …

1 Tuesday, 15 May 2018 Break08:00 - 09:30 FoyerRegistration and Welcome CoffeePlenary Session09:30 - 10:00 Congress HallWelcome Address 09:30 - 10:00 CIMT President Christoph HuberPlenary Session10:00 - 11:30 Congress HallCellular TherapyChair: Harpreet Singh (Immatics Biotechnologies, Houston, United States) 10:00 - 10:30 New modes of T-cell cancer recognition by dissection of immunotherapysuccesses Speaker: Andrew Sewell (Cardiff University, Cardiff, United Kingdom) 10:30 - 11:00 ADAP ting to solid tumors, advances and challenges for TCR T-cell therapy Speaker: Gwen Binder-Scholl (Adaptimmune, Philadelphia, United States) 11:00 - 11:30 TIL therapy in melanoma: history of clinical development, current statusand plans for the future Speaker: Rodabe Amaria (University of Texas MD Anderson Cancer Center,Houston, United States)Break11:30 - 13:30 FoyerLunchCorporate Supported Symposium12:00 - 13:00 Congress Hall"Immunooncology 2018 and beyond" supported by Bristol-Myers SquibbChair: Dirk J ger (National Center for Tumor Diseases, Heidelberg, Germany)Page 1 / 24 CIMT 2018 Scientific Programme 12:00 - 12:20 Immunooncology from mono- to combination therapy - a clinicalperspective Speaker: Viktor Gr nwald (Medical School Hannover (MHH), Hanover, Germany) 12:20 - 12:40 Resistance to immunotherapy Speaker: Guy Ungerechts (National Center for Tumor Diseases, Heidelberg,Germany) 12:40 - 13.

2 00 Biomarkers in immunooncology - can we predict the outcome of therapy? Speaker: Andreas Jung (Ludwig-Maximilians-Universit t, Munich, Germany)Plenary Session13:30 - 15:00 Congress HallCounteracting Immune EscapeChair: Cornelis Melief (ISA Pharmaceuticals, Leiden, Netherlands)Chair: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands) 13:30 - 14:00 TNFR family members and cancer immunotherapy: lessons from chronicinfection Speaker: Tania Watts (University of Toronto, Toronto, Canada) 14:00 - 14:30 Role of lymphatic vessels in shaping the tumor immunemicroenvironment Speaker: Melody Swartz (University of Chicago, Chicago, United States) 14:30 - 15:00 Regulation of dendritic cells in tumors Speaker: Jan P. B ttcher (Technical University Munich, Munich, Germany)Break15:00 - 16:00 FoyerCoffee BreakPoster Session15:30 - 18:00 East and West FoyersPoster Session - Therapeutic Vaccination Reinforcing dendritic cells for cancer immunotherapy: diverse ways and means to targetantigens to human skin Speaker: Lydia Bellmann (Medical University of Innsbruck, Innsbruck, Austria) A versatile, high-throughput HLA peptidomics pipeline for cancer neoepitope discovery Speaker: Leon Bichmann (Uni-Tuebingen, Tuebingen, Germany) Targeted LC-MS detection identifies novel immunogenic HLA-A2-restricted T cell epitopesderived from HPV16 E6 and E7 Speaker.

3 Maria Bonsack (German Cancer Research Center (DKFZ), Heidelberg, Germany) Predicting observed patient responses to a short-peptide cancer vaccine via clinical trialsimulations Speaker: Liam V Brown (University of Oxford, Oxford, United Kingdom) The Glioma Actively Personalized Vaccine Consortium (GAPVAC) presents the successfulclinical translation of mutated peptide vaccination Speaker: Valesca Bukur (Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz,Germany)Page 2 / 24 CIMT 2018 Scientific Programme HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial forhepatocellular carcinoma patients Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy) Dendritic cell-targeted nano-vaccines synergize with anti-PD-1/anti-OX40 for melanomatreatment Speaker: Joao Conniot (Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal) Molecular mechanism of immune cell activation by therapeutic melanoma vaccine Speaker: Patrycja Czerwi ska (Pozna University of Medical Sciences, Pozna , Poland) A cancer vaccine targeting many neo-antigens is required for efficient eradication of largetumors Speaker: Maria De Lucia (University of Naples Federico II, Naples, Italy) Successful completion of the Mutanome Engineered RNA Immuno-Therapy (MERIT) project Speaker.

4 Katrin Frenzel (BioNTech Group, Mainz, Germany) Bifunctional RNA-nanoparticles to enhance dendritic cell activation and enable MRI-baseddetection of dendritic cell migration to lymph nodes Speaker: Adam Grippin (University of Florida Brain Tumor Immunotherapy Program, Gainesville, UnitedStates) E6/E7 RNA(LIP): An RNA cancer vaccine for treatment of patients with HPV16-positivemalignancies Speaker: Christian Grunwitz (Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz,Germany) A novel rMVA combination immunotherapy triggers potent innate and adaptive immuneresponses against established tumors Speaker: Maria Hinterberger (Bavarian Nordic, Planegg, Germany) A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticlesencoding shared tumor antigens for immunotherapy of malignant melanoma Speaker: Robert A.

5 Jabulowsky (BioNTech AG, Mainz, Germany) Novel linear doggybone DNA vaccine induces anti-tumour immunity via STING andindependent of TLR9 Speaker: Cinderella Jawahar (University of Southampton, Southampton, United Kingdom) Nucleic Acid based TRL ligand loaded nanocomplexes act as standalone antitumor agents Speaker: G. Gokberk Kaya (Bilkent University, Ankara, Turkey) Discovery and vaccine development for hepatocellular carcinoma HEPAVAC Speaker: Markus W. L ffler (University of T bingen, T bingen, Germany) Retrospective analysis of neoantigen prediction methods Speaker: Martin L wer (TRON Translational Oncology at the University Medical Center of the JohannesGutenberg University Mainz gGmbH, Mainz, Germany) Modulating T cell immunity in tumors by targeting PD-L1 and neoantigens using a liveattenuated oral Salmonella platform Speaker: Heinz Lubenau (VAXIMM GmbH, Mannheim, Germany) Enrichment of gene modified cellular melanoma vaccines with melanoma stem cells orinducible pluripotent stem cells increases immunogenicity and clinical effectiveness in mice Speaker.

6 Andrzej Mackiewicz (Pozna University of Medical Sciences, Pozna , Poland) The immunopeptidomic landscape of breast cancer Speaker: Ana Marcu (University of Tuebingen, Tuebingen, Germany) Multivalent polymeric nanoparticles for combinatorial innovative colorectal cancerimmunotherapy and immunomodulation Speaker: Ana Isabel Matos (Instituto de Investiga o do Medicamento ( ), Faculdade deFarm cia da Universidade de Lisboa, Lisboa, Portugal)Page 3 / 24 CIMT 2018 Scientific Programme Ibrutinib in combination with T-cell based immunotherapy in chronic lymphocytic leukemia(CLL) mass spectrometry-based HLA ligandome analysis of primary CLL cells approvesstable presentation of leukemia-associated antigens Speaker: Annika Nelde (University of T bingen, Institute for Cell Biology, T bingen, Germany) Nanoparticle-based vaccine improved OX40 anti-tumor efficacy in breast cancer Speaker: Carina Peres (Research Institute for Medicines ( ), Faculty of Pharmacy,Universidade de Lisboa, Lisbon, Portugal) Analysis of the human tumor HLA peptidome based on patient derived xenografts in mice Speaker: Nataly Rijensky (Technion-Israel Institute of Technology, Haifa, Israel) Pseudocowpox (PCPV): a viral vector for cancer immunotherapy Speaker.

7 Karola Rittner (Transgene, Illkirch-Graffenstaden, France) Local radiotherapy and E7-RNA-LPX vaccination activate non-redundant mechanisms andlead to complete tumor rejection of well-established HPV16+ TC-1 tumors Speaker: Nadja Salomon (TRON, Mainz, Germany) Standard therapy supplemented with immunogenic cell death therapy during andsubsequent multimodal immunotherapy for GBM Speaker: Stefaan Van Gool (IOZK, K ln, Germany) NKG2A blockade potentiates CD8+ T-cell immunity induced by cancer vaccines Speaker: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands) Biomaterial-based scaffolds improve delivery of therapeutic nanoparticle cancer vaccines todendritic cells Speaker: Jorieke Weiden (Radboud Institute for Molecular Life Sciences, Radboud University MedicalCenter, Nijmegen, Netherlands) Exosomes co-encapsulating antigen and immunoadjuvants act as an effective therapeuticcancer vaccine Speaker: Muzaffer Yildirim (Bilkent University, Ankara, Turkey)Poster Session15:30 - 18:00 East and West FoyersPoster Session - Immunomonitoring Evaluation of immunological changes induced by primary treatment in ovarian cancerpatients Speaker: Thuy Linh Eline Achten (Katholieke Universiteit Leuven, Leuven, Belgium) Prognostic relevance of immunological changes during first line treatment in epithelialovarian carcinoma Speaker.

8 Tha s Baert (KU Leuven, Leuven, Belgium) Peripheral blood NKT-cell frequencies and their PD-1 expression levels identify stage IVmelanoma patients with poor overall survival under PD-1/CTLA-4 blockade Speaker: Jonas Bochem (University Medical Center T bingen, T bingen, Germany) T cell Elispot proficiency panel 2017/2018: Evaluating routine T cell Elispot assays Speaker: Liselotte Brix (Immudex, Copenhagen, Denmark) MHC class II Dextramers - A new tool for detection of antigen specific CD4+ T-cells Speaker: Liselotte Brix (Immudex, Copenhagen, Denmark) High-throughput screening of human tumor-antigen specific CD4 T cells, including neo-antigen reactive cells Speaker: Carla Costa-Nunes (Translational Tumor Immunology Group, Department of fundamentalOncology, University of Lausanne, Epalinges, Switzerland) Rapid Target Identification for T-Cell Immune Responses with SpotMixTM Peptide Pools Speaker: Maren Eckey (JPT Peptide Technologies GmbH, Berlin, Germany)Page 4 / 24 CIMT 2018 Scientific Programme MemoMAB: Gateway to human antibody repertoires Speaker: Christoph Esslinger (Memo Therapeutics AG, Zurich, Switzerland) CetuGEX and Cetuximab in recurrent/metastatic squamous cell carcinoma of the head andneck (RM-HNSCC) p16+ subgroup analysis of the phase 2 RESGEX study Speaker.

9 Beate Habel (Glycotope GmbH, Berlin, Germany) High dimensional analysis of the myeloid cell landscape in human breast cancer metastaticlymph nodes Speaker: Rodrigo Nalio Ramos (Institute Curie, Paris, France) Tumor infiltrating T cells: complete workflows allow faster and improved flow cytometricanalysis of syngeneic mouse tumors Speaker: Anne Richter (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) New and reproducible method for rapid, standardized PBMC preparation andcyroconservation within the scope of clinical trials Speaker: Anne Richter (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) Conventional and immune therapies influence the immune microenvironment of malignantbrain tumors Speaker: Matteo Riva (KU Leuven, Leuven, Belgium) The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictivefactor for epithelial ovarian cancer survival Speaker: Saskia Santegoets (Leiden University Medical Center, Leiden, Netherlands) An improved in vitro assay for monitoring antigen-specific T cell responses using synthetic20mer peptides Speaker: Juliane Schneider (University of T bingen, T bingen, Germany) The spleen functions as a window of a systemic r


Related search queries